The influence of prescription opioid use duration and dose on development of treatment resistant depression

Preventive Medicine

Volumn 91, Issue , 2016, Pages 110-116

  Scherrer, Jeffrey F ^a,b   Salas, Joanne ^a,b   Sullivan, Mark D ^c   Schneider, F David ^a   Bucholz, Kathleen K ^d   Burroughs, Thomas ^a   Copeland, Laurel ^e,f,g   Ahmedani, Brian ^h   Lustman, Patrick J ^d,i  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^f TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^g UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^h HENRY FORD HEALTH SYSTEM   (United States)

ⁱ VA St Louis Healthcare System   (United States)

Author keywords

Depression; Epidemiology; Opioids; Pain

Indexed keywords

CODEINE; FENTANYL; HYDROCODONE; HYDROMORPHONE; LEVORPHANOL; MORPHINE; OPIATE; OXYCODONE; OXYMORPHONE; PENTAZOCINE; PETHIDINE; NARCOTIC ANALGESIC AGENT;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PAIN; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK; TREATMENT DURATION; TREATMENT RESISTANT DEPRESSION; CHRONIC PAIN; GOVERNMENT; MIDDLE AGED; PROPENSITY SCORE; TIME FACTOR; UNITED STATES; VERY ELDERLY; VETERAN;

ADULT; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; CHRONIC PAIN; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; PROPENSITY SCORE; RETROSPECTIVE STUDIES; TIME FACTORS; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS; VETERANS;

EID: 84981743365     PISSN: 00917435     EISSN: 10960260     Source Type: Journal    
DOI: 10.1016/j.ypmed.2016.08.003     Document Type: Article

References (33)

1. Cole, S.R., Hernan, M.A., Constructing inverse probability weights for marginal structural models. Am. J. Epidemiol. 168 (2008), 656–664.
2. Corey-Lisle, P.K., Brinbam, H.G., Greenberg, P.E., Marynchenko, M.B., Claxton, A.J., Identification of a claims data ‘signature’ and economic consequences for treatment-resistant depression. J. Clin. Psychiatry 63 (2002), 717–726.
3. Curtis, L.H., Hammill, B.G., Eisenstein, E.L., Kramer, J.M., Anstrom, K.J., Using inverse probability-weighted estimators in comparative effectiveness analysis with observational databases. Med. Care 45 (2007), S103–S107.
4. Daniell, H.W., Opioid endocrinopathy in women consuming prescribed sustained-action opioids for control of nonmalignant pain. J. Pain 9 (2008), 28–36.
5. Dart, R.C., Surratt, H.L., Cicero, T.J., Parrino, M.W., Severtson, G., Bucher-Bartelson, B., et al. Trends in opioid analgesic abuse and mortality in the United States. N. Engl. J. Med. 372 (2015), 241–248.
6. Eaton, W.W., Medical and Psychiatric Comorbidity Over the Course of Life. 2006, American Psychiatric Publishing, Inc., Arlington VA.
7. Fava, M., Davidson, K.G., Definition and epidemiology of treatment-resistant depression. Psychiatr. Clin. N. Am. 19 (1996), 180–203.
8. Fava, M., Memisoglu, A., Thase, M.E., Bodkin, J.A., Trivedi, M.H., de Somer, M., et al. Opioid modulation with burprenorphine/samidorphan as adjuntive treatment for inadequate response to antidepressants: a randomized double-blind placebo controlled trial. Am. J. Psychiatry 173 (2016), 499–508.
9. Glassman, A., Maj, M., Satrorius, N., Depression and Heart Disease. 2011, John Wiley and Sons Ltd., West Sussex, UK.
10. Grattan, A., Sullivan, M.D., Saunders, K.W., Campbell, C.I., Von Korff, M.R., Depression and prescription opioid misuse among chronic opioid therapy recipients with no history of substance abuse. Ann. Fam. Med. 10:4 (2012), 304–311 (Epub 2012/07/11).
11. Howe, C.Q., Sullivan, M.D., The missing ‘P’ in pain management: how the current opioid epidemic highlights the need for psychiatric services in chronic pain care. Gen. Hosp. Psychiatry 36:1 (2014), 99–104.
12. Hygiene NYCDoHaM, Morphine Milligram Equivalent (MME) Calculator. Available from http://www.nyc.gov/html/doh/html/mental/MME.html.
13. Informatics IIfH, (eds.) The Use of Medicines in the United States: Review of 2010, 2011.
14. Karp, J.F., Butters, M.A., Begley, A.E., Miller, M.D., Lenze, E.J., Blumberger, D.M., et al. Safety, tolerability, and clinical effect of low-dose buprenorphine for treatment-resistant depression in midlife and older adults. J. Clin. Psychiatry 75 (2014), e785–e793.
15. Kilpatrick, R.D.G.D., Brookhart, M.A., Polley, E., Rothman, K.J., Bradbury, B.D., Exploring large weight deletion and the ability to balance confounders when using inverse probability of treatment weighting in the presence of rate treatment decisions. Pharmacoepidemiol. Drug Saf. 22 (2013), 111–121.
16. Kubitz, N., Mehra, M., Potluri, R.C., Garg, N., Cossrow, N., Characterization of treatment resistant depression episodes in a cohort of patients from a U.S. commercial claims database. PLoS One, 8, 2013, e76882.
17. Onen, S.H., Onen, F., Courpron, P., Dubray, C., How pain and analgesics disturb sleep. Clin. J. Pain 21 (2005), 422–431.
18. Russell, J.M., Hawkins, K., Ozminkowski, R.J., Orsini, L., Crown, W.H., Kennedy, S., et al. The cost of treatment-resistant depression. J. Clin. Psychiatry 65 (2004), 341–347.
19. Scherrer, J.F., Chrusciel, T., Garfield, L.D., Freedland, K.E., Carney, R.M., Lustman, P.J., et al. Treatment-resistant and insufficiently treated depresion and all-cause mortality following myocardial infarction. Br. J. Psychiatry 200 (2012), 137–142.
20. Scherrer, J.F., Salas, J., Copeland, L.A., Stock, E.M., Ahmedani, B.K., Sullivan, M., et al. Prescription opioid duration, dose, and increased risk of depression in 3 large patient populations. Ann. Fam. Med. 14 (2016), 54–62.
21. Scherrer, J.F., Salas, J., Copeland, L.A., Stock, E.M., Schneider, F.D., Sullivan, M.D., et al. Increased risk of depression recurrence after initiation of prescription opioids in noncancer pain patients. J. Pain 17:4 (2016), 473–482.
22. Scherrer, J.F., Salas, J., Copeland, L.A., Stock, E.M., Schneider, F.D., Sullivan, M.D., et al. Increased risk of depression recurrence after initiation of prescription opioids in non-cancer pain patients. J. Pain 17 (2016), 473–482.
23. Scherrer, J.F., Salas, J., Lustman, P.J., Burge, S., Schneider, F.D., Texas RRNo. Change in opioid dose and change in depression in a longitudinal primary care patient cohort. Pain 156:2 (2015), 348–355.
24. Scherrer, J.F., Svrakic, D.M., Freedland, K.E., Chrusciel, T., Balasubramanian, S., Bucholz, K.K., et al. Prescription opioid analgesics increase the risk of depression. J. Gen. Intern. Med. 29:3 (2014), 491–499.
25. Seal, K.H., Shi, Y., Cohen, G., Cohen, B.E., Maguen, S., Krebs, E.E., et al. Association of mental health disorders with prescription opioids and high-risk opioid use in US Veterans of Iraq and Afghanistan. JAMA 307 (2012), 940–947.
26. Smith, H.S., Elliott, J.A., Opioid-induced androgen deficiency (OPIAD). Pain Physician 15 (2012), ES145–ES156.
27. Smith, K., Mattick, R.P., Bruno, R., Nielsen, S., Cohen, M., Campbell, G., Larance, B., Farrell, M., Degenhardt, L., Factors associated with the development of depression in chronic non-cancer pain patients following the onset of opioid treatment for pain. J. Affect. Disord. 184 (2015), 72–80.
28. Solberg, L.I., Engebretson, K.I., Sperl-Hillen, J.M., Hroscikoski, M.C., O'Connor, P.G., Are claims data accurate enough to identify patients for performance measures or quality improvement? The case of diabetes, heart disease and depression. Am. J. Med. Qual. 21 (2006), 238–245.
29. Sullivan, M.D., Who gets high-dose opioid therapy for chronic non-cancer pain?. Pain 151:3 (2010), 567–568 (Epub 2010/09/10).
30. Sullivan, M.D., Edlund, M.J., Zhang, L., Unutzer, J., Wells, K.B., Association between mental health disorders, problem drug use, and regular prescription opioid use. Arch. Intern. Med. 166:19 (2006), 2087–2093 (Epub 2006/10/25).
31. Terenius, L., Wahlstrom, A., Agren, H., Naloxone (Narcan) treatment in depression: clinical observations and effects on CSF endorphins and monoamine metabolites. Psychopharmacology 54 (1977), 31–33.
32. Thase, M.E., Rush, A.J., When at first you don't succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry 58:Suppl. 13 (1997), 23–29.
33. Vos, T., Barber, R.M., Bell, B., Bertozzi-Villa, A., Biryukov, S., Bollinger, I., et al. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 386 (2015), 743–800.